| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 134,697 | 155,464 | 193,389 | 156,172 |
| Marketable securities | 241,289 | 294,420 | 317,655 | 303,479 |
| Accounts receivable | 9,131 | 9,468 | 11,050 | 11,353 |
| Prepaid expenses and other current assets | 81,332 | 68,359 | 59,847 | 24,941 |
| Total current assets | 466,449 | 527,711 | 581,941 | 495,945 |
| Marketable securities - noncurrent | 141,261 | 155,250 | 158,814 | 170,855 |
| Total property and equipment | NaN | 76,277 | NaN | NaN |
| Less accumulated depreciation and amortization | NaN | 58,606 | NaN | NaN |
| Property and equipment, net | 15,516 | 17,671 | 20,421 | 22,806 |
| Operating lease right-of-use assets | 97,543 | 105,955 | 117,883 | 129,045 |
| Investment in kyverna | 10,130 | NaN | NaN | NaN |
| Other investments | 11,424 | NaN | NaN | NaN |
| Restricted cash equivalents, long-term | 15,404 | NaN | NaN | NaN |
| Prepaid expenses and other assets, long-term | 1,052 | NaN | NaN | NaN |
| Investments and other assets | 38,010 | 35,540 | 46,216 | 80,243 |
| Total assets | 758,779 | 842,127 | 925,275 | 898,894 |
| Accounts payable | 18,800 | 20,252 | 13,260 | 9,802 |
| Accrued research and development | 11,790 | NaN | NaN | NaN |
| Employee compensation and benefits | 9,323 | NaN | NaN | NaN |
| Accrued legal and professional expenses | 8,703 | NaN | NaN | NaN |
| Accrued other | 8,104 | NaN | NaN | NaN |
| Accrued expenses | 37,920 | 49,862 | 40,841 | 41,553 |
| Current portion of operating lease liability | 19,095 | 26,480 | 27,378 | 26,990 |
| Current portion of deferred revenue | 630 | 7,290 | 12,247 | 17,154 |
| Total current liabilities | 76,445 | 103,884 | 93,726 | 95,499 |
| Deferred revenue, net of current portion | NaN | 0 | 12,539 | 12,539 |
| Long-term operating lease liability | 61,395 | 66,849 | 70,588 | 75,601 |
| Total liabilities | 137,840 | 170,733 | 176,853 | 183,639 |
| Common stock, 0.0001 par value 240,000,000 shares authorized at mrach 31, 2026 and december 31, 2025 120,447,521 and 116,317,060 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 12 | 12 | 12 | 10 |
| Additional paid-in capital | 3,307,492 | 3,260,444 | 3,241,728 | 3,107,576 |
| Accumulated other comprehensive income | -240 | 1,032 | 990 | 653 |
| Accumulated deficit | -2,686,325 | -2,590,094 | -2,494,308 | -2,392,984 |
| Total stockholders equity | 620,939 | 671,394 | 748,422 | 715,255 |
| Total liabilities and stockholders' equity | 758,779 | 842,127 | 925,275 | 898,894 |
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)